Inegy

Simvastatin and ezetimibe, the active ingredients in Inegy, are HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as an oral tablet for oral use. They are indicated for lowering elevated cholesterol and triglyceride levels in patients with hypercholesterolemia or mixed dyslipidemia. GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.

Hypercholesterolemia: lowers LDL‑cholesterol in patients with elevated cholesterol levels. Mixed dyslipidemia: improves overall lipid profile by reducing LDL‑C and triglycerides while modestly raising HDL‑C. Cardiovascular risk reduction: used as part of therapy to decrease the risk of atherosclerotic events in high‑risk individuals.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: including nausea, abdominal pain, or diarrhea. - Myalgia: muscle aches without significant CK elevation. - Elevated liver enzymes: transient increases in ALT/AST. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with marked CK rise. - Acute liver injury: significant hepatitis or hepatic failure. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Myopathy: muscle weakness with CK elevation. - Pancreatitis: rare inflammation of the pancreas.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

Liver function monitoring: obtain baseline and periodic ALT/AST levels. Renal impairment assessment: evaluate kidney function and adjust if necessary. Drug interaction review: avoid concomitant strong CYP3A4 inhibitors. Pregnancy and lactation: use only if potential benefit justifies the risk. Muscle symptom vigilance: discontinue if unexplained muscle pain with CK elevation occurs. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Inegy interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase simvastatin exposure → heightened myopathy risk. - Gemfibrozil: synergistic effect on muscle toxicity. - Cyclosporine: raises plasma concentrations of both components. - High‑dose niacin: amplifies risk of hepatotoxicity and muscle injury.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Antacids containing aluminum or magnesium: can reduce ezetimibe absorption. - Other statins (e.g., lovastatin): additive risk of muscle adverse events.